SYNTHESIS OF QUINAZOLINE DERIVATIVES AS GEFITINIB INTERMEDIATES
Cancer appears to be the second cause of death in the worldwide. Lung cancer is the second most common cancer variety with the highest death rate. Lung cancer is a disease caused by gene mutations in the Epidermal Growth Factor Receptor (EGFR) signalling pathway which causes excessive phosphor...
Saved in:
| Main Author: | |
|---|---|
| Format: | Final Project |
| Language: | Indonesia |
| Subjects: | |
| Online Access: | https://digilib.itb.ac.id/gdl/view/81485 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Institut Teknologi Bandung |
| Language: | Indonesia |
| Summary: | Cancer appears to be the second cause of death in the worldwide. Lung cancer is the second most
common cancer variety with the highest death rate. Lung cancer is a disease caused by gene mutations
in the Epidermal Growth Factor Receptor (EGFR) signalling pathway which causes excessive
phosphorylation. One of the medications used for lung cancer is gefitinib. Gefitinib is a molecule that
has an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor activity. In the previous
study, the most important step in the synthesis of gefitinib was the demethylation process of the
methoxy group at position 6 of 6,7-dimethoxy-3,4-dihydroquinazolin-4-one (1) using L-methionine
and methanesulfonic acid to produce 6-hydroxy-7- methoxy-3,4-dihydroquinazoline-4-one (2), with
a yield of 46%. Therefore, this study aims to optimize the demethylation process of 6-hydroxy-7-
methoxy-3,4-dihydroquinazolin-4-one (2) by varying the temperature and equivalent, then the
optimization results ware reacted with 4-(3-chloro-4-fluorophenylamino)-6,7-dimethoxy quinazoline
(3) to produce 4-(3-chloro-4-fluorophenylamino)-6-hydroxy-7-methoxy quinazoline (4).
Subsequently, the Williamson ether reaction was carried out to produce the intermediates N-(3-
chloro-4-fluorophenyl)-6-(3-chloropropoxy)-7-methoxyquinazoline-4-amine (5) and 6-(4-
bromobutoxy)-N-(3 -chloro-4-fluorophenyl)-7-methoxyquinazoline-4-amine (6). In this study,
compound (2) was successfully synthesized with optimum reaction conditions at a temperature 120°C
and equivalent ratio of precursor and L-methionine of 1:1,5 for 1 hour reaction with a HPLC yield of
74,4%, compound (4) with a yield of 49% , compound (5) with a yield of 31%, and compound (6)
with a yield of 3.5%. The synthesized product was characterized by NMR spectroscopy (1H and 13C)
and mass spectrometry |
|---|